AbbVie Inc.

News & Events

Press Releases

In The Media

1. BOTOX® Cosmetic (onabotulinumtoxinA) Selects This Year's Entrepreneurs for The Confidence Project

   PR Newswire JUL 22, 2025 8:00 AM EDT
   BOTOX® Cosmetic (onabotulinumtoxinA) Selects This Year's Entrepreneurs for The Confidence Pr...
   READ ARTICLE

2. Refresh Releases First of its Kind Eye Drop for Dry Eyes

   Canada Newswire JUL 11, 2025 5:35 PM EDT
   Refresh Releases First of its Kind Eye Drop for Dry Eyes Canada NewsWire Refr...
   READ ARTICLE

3. Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody

   GlobeNewswire JUL 10, 2025 7:35 AM EDT
   ISB 2001 is currently in Phase 1 clinical trial in patients with relapsed/refractory multipl...
   READ ARTICLE

4. AbbVie and Ichnos Glenmark Innovation (IGI) Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody

   PR Newswire JUL 10, 2025 7:30 AM EDT
   AbbVie and Ichnos Glenmark Innovation (IGI) Announce Exclusive Global Licensing Agreement for ISB...
   READ ARTICLE

5. AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology

   PR Newswire JUN 30, 2025 8:31 AM EDT
   AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient ...
   READ ARTICLE

6. U.S. Food and Drug Administration Accepts for Review Allergan Aesthetics Premarket Approval Application for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance

   PR Newswire JUN 30, 2025 8:25 AM EDT
   U.S. Food and Drug Administration Accepts for Review Allergan Aesthetics Premarket Approval Appli...
   READ ARTICLE

7. AbbVie to Host Second-Quarter 2025 Earnings Conference Call

   PR Newswire JUN 30, 2025 8:00 AM EDT
   AbbVie to Host Second-Quarter 2025 Earnings Conference Call PR Newswire NOR...
   READ ARTICLE

8. AbbVie Declares Quarterly Dividend

   PR Newswire JUN 20, 2025 8:00 AM EDT
   AbbVie Declares Quarterly Dividend PR Newswire NORTH CHICAGO, Ill. , ...
   READ ARTICLE

9. AbbVie Announces New Data Demonstrating Atogepant (QULIPTA® / AQUIPTA®) Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention

   PR Newswire JUN 18, 2025 7:15 AM EDT
   AbbVie Announces New Data Demonstrating Atogepant (QULIPTA® / AQUIPTA®) Achieves Superi...
   READ ARTICLE

10. AbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes

    PR Newswire JUN 16, 2025 9:00 AM EDT
    AbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes ...
    READ ARTICLE